You need to enable JavaScript to run this app.
Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes
Regulatory News
Zachary Brennan
Regulatory NewsZachary Brennan
Regulatory NewsZachary Brennan